Separate terms with OR to return results that match either term.
 
Clear All

9,180 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Ascending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63759-3029-01 63759-3029 gemcitabine GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
62756-0008-60 62756-0008 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0073-60 62756-0073 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0102-60 62756-0102 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0219-60 62756-0219 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0321-60 62756-0321 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0438-60 62756-0438 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0533-60 62756-0533 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0614-60 62756-0614 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0746-60 62756-0746 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0974-60 62756-0974 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
50742-0496-26 50742-0496 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 26, 2019 In Use
50742-0497-53 50742-0497 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 26, 2019 In Use
25021-0239-05 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Sept. 30, 2020 No Longer Used
25021-0239-26 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Feb. 28, 2021 No Longer Used
25021-0239-52 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Aug. 31, 2020 No Longer Used
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
00338-3991-01 00338-3991 ifosfamide Ifex 1.0 g/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 30, 1988 In Use
00338-3993-01 00338-3993 ifosfamide Ifex 3.0 g/60mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 30, 1988 In Use
00378-2245-77 00378-2245 imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
00378-2246-93 00378-2246 imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
68001-0490-05 68001-0490 imatinib mesylate imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 26, 2021 In Use
64679-0794-01 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-02 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-03 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
67877-0633-90 67877-0633 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
67877-0634-30 67877-0634 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
72485-0202-90 72485-0202 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
72485-0203-30 72485-0203 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
72730-0101-01 72730-0101 infigratinib TRUSELTIQ 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0506-01 72730-0506 infigratinib TRUSELTIQ 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
10631-0002-31 10631-0002 isotretinoin Absorica LD 8.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0003-31 10631-0003 isotretinoin Absorica LD 16.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0004-31 10631-0004 isotretinoin Absorica LD 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0005-31 10631-0005 isotretinoin Absorica LD 24.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0006-31 10631-0006 isotretinoin Absorica LD 28.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0007-31 10631-0007 isotretinoin Absorica LD 32.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sept. 29, 2020 In Use
70518-1869-00 70518-1869 letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Feb. 13, 2019 Sept. 23, 2019 No Longer Used
00078-0916-61 00078-0916 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal May 4, 2017 In Use
00078-0923-61 00078-0923 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal May 4, 2017 In Use

Found 9,180 results in 21 millisecondsExport these results